huN901-DM1: Phase I/II

In the Phase I portion of a U.S. Phase I/II trial in 32 patients, the maximum tolerated dose was 60 mg/m 2 when huN901-DM1 was given once weekly for 4 weeks. IMGN said toxicities were modest and preli...